Shots:

• The P-IIb trial (KEYNOTE-942/mRNA-4157-P201) evaluates mRNA-4157/V940 + Keytruda (200mg, q3w for ~18 cycles) vs Keytruda alone in 157 patients with stage III/IV melanoma
• The results showed a significant & clinical improvement in the 1EPs of RFS, 44% reduction in risk of recurrence or death. The AEs & safety profile was consistent with prior reported studies, and serious TRAEs were reported in (14.4% vs 10%)
• The companies plan to discuss the results with regulatory authorities and also plan to initiate a P-III study in 2023. Under an agreement with Moderna, Merck had exercised its option to develop & commercialize mRNA-4157/V940 & both companies will share equal costs and profits

Ref: Moderna | Image: Moderna